PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients
Shares of ProMIS Neurosciences (PMN) surged 160% on Monday following news that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its lead Alzheimer’s candidate, PMN310. The designation marks a major milestone for the clinical-stage biotech firm, reinforcing the potential of PMN310 to address one of the most pressing unmet needs in neurodegenerative medicine.
PMN310 is a novel monoclonal antibody designed to selectively target only the most toxic, misfolded forms of amyloid-beta—proteins believed to drive the progression of Alzheimer’s disease (AD). By avoiding the broader binding seen in current therapies, ProMIS hopes to reduce serious side effects such as brain swelling and bleeding, known as ARIA, while delivering improved therapeutic outcomes.
“The FDA’s Fast Track designation not only validates the scientific approach behind PMN310 but also provides a clear regulatory pathway to expedite its development,” said Neil Warma, President and CEO of ProMIS Neurosciences. “We are committed to advancing this next-generation Alzheimer’s treatment with both urgency and scientific rigor.”
The Fast Track status enables more frequent interactions with the FDA, paving the way for accelerated clinical milestones and potentially earlier approval. The ongoing PRECISE-AD Phase 1b trial is assessing PMN310’s safety, tolerability, pharmacokinetics, and biomarker effects in patients with early Alzheimer’s. Interim data is expected in the second quarter of 2026, with final results anticipated by the end of next year.
Alzheimer’s affects over 6 million Americans and remains a leading cause of death and disability. Despite recent advances, the demand for more targeted and safer therapies continues to grow—positioning ProMIS and PMN310 as promising contenders in the evolving AD treatment landscape.
You might like this article:Michael Saylor’s Strategy Now Holds Over 3% of All Bitcoin Ever Minted
